India · Delayed Price · Currency is INR Aptus Pharma Statistics
Total Valuation
Aptus Pharma has a market cap or net worth of INR 8.10 billion. The enterprise value is 8.20 billion.
| Market Cap | 8.10B |
| Enterprise Value | 8.20B |
Important Dates
The last earnings date was Tuesday, October 20, 2026.
| Earnings Date | Oct 20, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Aptus Pharma has 17.15 million shares outstanding. The number of shares has decreased by -2.95% in one year.
| Current Share Class | 17.15M |
| Shares Outstanding | 17.15M |
| Shares Change (YoY) | -2.95% |
| Shares Change (QoQ) | +0.52% |
| Owned by Insiders (%) | 72.89% |
| Owned by Institutions (%) | 6.38% |
| Float | 3.69M |
Valuation Ratios
The trailing PE ratio is 101.22.
| PE Ratio | 101.22 |
| Forward PE | n/a |
| PS Ratio | 9.98 |
| PB Ratio | 28.49 |
| P/TBV Ratio | 28.54 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 103.14 |
| EV / Sales | 10.11 |
| EV / EBITDA | 66.18 |
| EV / EBIT | 69.50 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.67, with a Debt / Equity ratio of 0.43.
| Current Ratio | 2.67 |
| Quick Ratio | 1.63 |
| Debt / Equity | 0.43 |
| Debt / EBITDA | 0.98 |
| Debt / FCF | n/a |
| Interest Coverage | 10.86 |
Financial Efficiency
Return on equity (ROE) is 31.72% and return on invested capital (ROIC) is 22.32%.
| Return on Equity (ROE) | 31.72% |
| Return on Assets (ROA) | 15.66% |
| Return on Invested Capital (ROIC) | 22.32% |
| Return on Capital Employed (ROCE) | 32.93% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | 8.91M |
| Profits Per Employee | 873,582 |
| Employee Count | 91 |
| Asset Turnover | 1.72 |
| Inventory Turnover | 3.29 |
Taxes
In the past 12 months, Aptus Pharma has paid 29.00 million in taxes.
| Income Tax | 29.00M |
| Effective Tax Rate | 26.73% |
Stock Price Statistics
The stock price has increased by +835.92% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +835.92% |
| 50-Day Moving Average | 364.32 |
| 200-Day Moving Average | 213.82 |
| Relative Strength Index (RSI) | 69.63 |
| Average Volume (20 Days) | 18,060 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Aptus Pharma had revenue of INR 811.18 million and earned 79.50 million in profits. Earnings per share was 4.66.
| Revenue | 811.18M |
| Gross Profit | 374.14M |
| Operating Income | 117.98M |
| Pretax Income | 108.50M |
| Net Income | 79.50M |
| EBITDA | 123.91M |
| EBIT | 117.98M |
| Earnings Per Share (EPS) | 4.66 |
Balance Sheet
The company has 18.02 million in cash and 121.11 million in debt, with a net cash position of -103.09 million or -6.01 per share.
| Cash & Cash Equivalents | 18.02M |
| Total Debt | 121.11M |
| Net Cash | -103.09M |
| Net Cash Per Share | -6.01 |
| Equity (Book Value) | 284.23M |
| Book Value Per Share | 16.57 |
| Working Capital | 312.31M |
Cash Flow
In the last 12 months, operating cash flow was -114.85 million and capital expenditures -25.90 million, giving a free cash flow of -140.76 million.
| Operating Cash Flow | -114.85M |
| Capital Expenditures | -25.90M |
| Depreciation & Amortization | 5.93M |
| Net Borrowing | 39.76M |
| Free Cash Flow | -140.76M |
| FCF Per Share | -8.21 |
Margins
Gross margin is 46.12%, with operating and profit margins of 14.54% and 9.80%.
| Gross Margin | 46.12% |
| Operating Margin | 14.54% |
| Pretax Margin | 13.38% |
| Profit Margin | 9.80% |
| EBITDA Margin | 15.28% |
| EBIT Margin | 14.54% |
| FCF Margin | n/a |
Dividends & Yields
Aptus Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | 2.95% |
| Shareholder Yield | 2.95% |
| Earnings Yield | 0.99% |
| FCF Yield | -1.74% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on May 12, 2026. It was a forward split with a ratio of 2.5.
| Last Split Date | May 12, 2026 |
| Split Type | Forward |
| Split Ratio | 2.5 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 3 |